Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joohyuk Sohn

Showing results (61-70 of 130) with videos related to

Pageof 13
Sort By:
The Lancet. Oncology|December 7, 2019
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trialRobert Coleman, Dianne M Finkelstein, Carlos Barrios, et al.
British Journal of Cancer|June 23, 2021
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancerHoward A Burris, Arlene Chan, Aditya Bardia, et al.
Therapeutic Advances in Medical Oncology|December 20, 2021
Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)Sung-Bae Kim, Jae Hong Seo, Jin-Hee Ahn, et al.
Molecular Cancer Therapeutics|December 7, 2018
Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast CancerShuying Liu, Shunqiang Li, Bailiang Wang, et al.
Journal of Global Oncology|August 8, 2018
Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical TrialsChia-Jui Yen, Kei Muro, Tae-Won Kim, et al.
Cancer Science|March 9, 2021
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trialsMasakazu Toi, Kenichi Inoue, Norikazu Masuda, et al.
The New England Journal of Medicine|October 22, 2025
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast CancerJavier Cortés, Kevin Punie, Carlos Barrios, et al.
Journal of Breast Cancer|April 1, 2026
Germline Mutations Related to Complete Remission After Neoadjuvant Chemotherapy in Patients With Triple-negative Breast CancerJee Hyun Ahn, Ji Soo Park, Dongju Won, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2018
Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric StudyShin-Ae Kang, Jye Swei Guan, Hock Jin Tan, et al.
Breast Cancer Research : BCR|March 12, 2025
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 studyRebecca Dent, Javier Cortés, Yeon Hee Park, et al.
Pageof 13

Showing results (61-70 of 130) with videos related to

Sort By:
Pageof 13
The Lancet. Oncology|December 7, 2019
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trialRobert Coleman, Dianne M Finkelstein, Carlos Barrios, et al.
British Journal of Cancer|June 23, 2021
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancerHoward A Burris, Arlene Chan, Aditya Bardia, et al.
Therapeutic Advances in Medical Oncology|December 20, 2021
Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)Sung-Bae Kim, Jae Hong Seo, Jin-Hee Ahn, et al.
Molecular Cancer Therapeutics|December 7, 2018
Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast CancerShuying Liu, Shunqiang Li, Bailiang Wang, et al.
Journal of Global Oncology|August 8, 2018
Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical TrialsChia-Jui Yen, Kei Muro, Tae-Won Kim, et al.
Cancer Science|March 9, 2021
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trialsMasakazu Toi, Kenichi Inoue, Norikazu Masuda, et al.
The New England Journal of Medicine|October 22, 2025
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast CancerJavier Cortés, Kevin Punie, Carlos Barrios, et al.
Journal of Breast Cancer|April 1, 2026
Germline Mutations Related to Complete Remission After Neoadjuvant Chemotherapy in Patients With Triple-negative Breast CancerJee Hyun Ahn, Ji Soo Park, Dongju Won, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2018
Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric StudyShin-Ae Kang, Jye Swei Guan, Hock Jin Tan, et al.
Breast Cancer Research : BCR|March 12, 2025
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 studyRebecca Dent, Javier Cortés, Yeon Hee Park, et al.
Pageof 13